WOBURN, Mass., March 5 /PRNewswire/ -- U.S. Genomics announced today that Dr. Howard C. Berg, the Herchel Smith Professor of Physics the Professor of Molecular and Cellular Biology and a Member of the Rowland Institute at Harvard University, is the recipient of the Biophysical Society’s annual award for Outstanding Investigator in Single Molecule Biology, sponsored by U.S. Genomics. The award will be presented this evening at the 51st Annual Meeting of the Biophysical Society in Baltimore, Maryland. The purpose of the Biophysical Society’s Awards Program is to honor its members, recognize excellence in biophysics, and promote greater interaction among life scientists throughout the world.
“Conducting critical research focused on better understanding the motility system and behavior of flagellated bacteria is only one of Dr. Berg’s numerous achievements. He has demonstrated the importance of working at the level of single molecules to discover the basis of fundamental cellular processes,” said John J. Canepa, CEO of U.S. Genomics. “As the pioneer of single molecule biology tools, U.S. Genomics is proud to sponsor an award that recognizes and promotes outstanding contributions in this field. The Biophysical Society Annual Meeting offers a premier venue in which to acknowledge Dr. Berg’s great achievements.”
“It seems altogether fitting that the Biophysical Society’s Single Molecule Biophysics Award be bestowed this year upon Howard C. Berg,” said Joe Falke, incoming President of the Biophysical Society. “Dr. Berg not only helped to found this modern field by establishing the very first single-motor assay, but continues today to lead the way with his unique and innovative approaches to single-cell and single-molecule physiology.”
Descriptions and criteria of the award are posted at www.biophysics.org/opportunities.
About U.S. Genomics, Inc.
U.S. Genomics is pioneering single molecule biology technologies for life science and biodefense applications by combining advances in microfluidics, optical engineering, and novel labeling strategies. Using its DNA mapping technology, the Company is developing sophisticated biological sensors for the detection and identification of pathogens and biomarkers in the air, human serum and other biologically relevant materials. The Company’s biodefense focus on airborne pathogens has been funded in part by $24 million in contracts from the U.S. Department of Homeland Security. The Trilogy(R) platform enables the direct detection and analysis of individual molecules of DNA, RNA, and proteins without the need for amplification. U.S. Genomics’ portfolio of products will further a greater understanding of genetics and disease pathways and will ultimately lead to more effective therapeutics, diagnostics, and biodefense applications. For more information, please visit www.usgenomics.com.
About the Biophysical Society
The Biophysical Society, founded in 1956, is a professional, scientific society established to encourage development and dissemination of knowledge in biophysics. The Society promotes growth in this expanding field through its annual meeting, bimonthly journal, and committee and outreach activities. Its 8000 members are located in the U.S. and around the world, where they teach and conduct research in colleges, universities, laboratories, government agencies, and industry.
Trilogy is a registered trademark and Direct (as in Direct miRNA), Digital DNA and U.S. Genomics are trademarks of U.S. Genomics, Inc.
U.S. Genomics, Inc.
CONTACT: John Canepa, President and CEO of U.S. Genomics, +1-781-939-6424,jcanepa@usgenomics.com, or Ellen R. Weiss, Public Affairs Manager of TheBiophysical Society, +1-301-634-7176, eweiss@biophysics.org
Web site: http://www.usgenomics.com/
